- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Fall 2016
Case Name | Date Filed | Judge | Drug | Patent No(s). |
---|---|---|---|---|
Apotex Inc. v. Eli Lilly & Co., IPR2016-01190 (PTAB) | July 1, 2016 | N/A | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
Apotex Inc. v. Eli Lilly & Co., IPR2016-01191 (PTAB) | July 1, 2016 | N/A | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
Teva Pharms. USA, Inc. v. Eli Lilly & Co., IPR2016-01340 (PTAB) | July 1, 2016 | N/A | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
Teva Pharms. USA, Inc. v. Eli Lilly & Co., IPR2016-01341 (PTAB) | July 1, 2016 | N/A | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
Teva Pharms. USA, Inc. v. Eli Lilly & Co., IPR2016-01343 (PTAB) | July 1, 2016 | N/A | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
Orexo AB v. Actavis Elizabeth LLC, 16-0582 (D. Del.) | July 7, 2016 | Hon. Sue L. Robinson | Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride sublingual tablets) | 9,259,421 |
AstraZeneca AB v. Apotex Corp., 16-0583 (D. Del.) | July 7, 2016 | Hon. Gregory M. Sleet | Onglyza® (saxagliptin hydrochloride tablets) | RE44,186 |
Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution Inc., 16-0592 (D. Del.) | July 8, 2016 | Hon. Gregory M. Sleet | INOmax® (nitric oxide for inhalation) |
9,265,911
9,295,802
9,279,794
|
Gilead Sciences, Inc. v. Aurobindo Pharma Ltd., 16-4178 (D.N.J.) | July 8, 2016 | Hon. Renee Marie Bumb | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245
6,703,396
8,592,397
8,716,264
|
Mylan Inc. v. Dr. Falk Pharma GmbH, IPR2016-01386 (PTAB) | July 8, 2016 | N/A | Apriso® (mesalamine extended-release capsules) | 8,865,688 |
Teva Pharms. USA, Inc. v. Eli Lilly & Co., IPR2016-01393 (PTAB) | July 8, 2016 | N/A | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
Imprimis Pharms., Inc. v. Alcon Pharms. Ltd., 16-1794 (S.D. Cal.) | July 11, 2016 | Hon. Marilyn L. Huff |
Vigamox® (moxifloxacin hydrochloride ophthalmic solution)
Moxeza® (moxifloxacin hydrochloride ophthalmic solution)
|
6,716,830
7,671,070
|
Fohill Capital Partners v. Dr. Falk Pharma GmbH, IPR2016-01409 (PTAB) | July 11, 2016 | N/A | Apriso® (mesalamine extended-release capsules) | 8,865,688 |
Tris Pharma, Inc. v. Actavis Elizabeth LLC, 16-0603 (D. Del.) | July 12, 2016 | Hon. Gregory M. Sleet | QuilliChew ER® (methylphenidate hydrochloride extended-release chewable tablets) |
8,202,537
8,287,903
8,999,386
9,295,642
|
Helsinn Healthcare S.A. v. Zydus Pharms. (USA) Inc., 16-4239 (D.N.J.) | July 12, 2016 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride injection) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
Amneal Pharms. LLC v. Yeda Research & Development Co. Ltd., PGR2016-00028 (PTAB) | July 12, 2016 | N/A | Copaxone® (glatiramer acetate injection) | 9,155,776 |
Actavis Elizabeth LLC v. Novartis Pharms. Corp., 16-0604 (D. Del.) | July 13, 2016 | Hon. Richard G. Andrews | Jadenu® (deferasirox tablets) | 9,283,209 |
Shionogi Inc. v. Actavis Labs. UT, Inc., 16-0606 (D. Del.) | July 14, 2016 | Hon. Leonard P. Stark | Ulesfia® (benzyl alcohol lotion) |
6,793,931
7,294,342
|
Apotex Inc. v. Eli Lilly & Co., IPR2016-01429 (PTAB) | July 14, 2016 | N/A | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
Valeant Pharms. Luxembourg S.A.R.L. v. Actavis Labs. UT, Inc., 16-4344 (D.N.J.) | July 15, 2016 | Hon. Jose L. Linares | Carac® (fluorouracil topical cream) | 6,670,335 |
Amneal Pharms. LLC v. Purdue Pharma L.P., IPR2016-01412 (PTAB) | July 15, 2016 | N/A | OxyContin® (oxycodone hydrochloride extended-release tablets) | 9,034,376 |
Amneal Pharms. LLC v. Purdue Pharma L.P., IPR2016-01413 (PTAB) | July 15, 2016 | N/A | OxyContin® (oxycodone hydrochloride extended-release tablets) | 9,034,376 |
Roxane Labs., Inc. v. Novartis AG, IPR2016-01461 (PTAB) | July 19, 2016 | N/A | Afinitor® (everolimus tablets) | 9,006,224 |
Allergan, Inc. v. TWi Pharms., Inc., 16-0620 (D. Del.) | July 20, 2016 | Hon. Gregory M. Sleet | Restasis® (cyclosporine ophthalmic emulsion) |
8,629,111
8,633,162
8,642,556
8,648,048
8,685,930
9,248,191
|
AstraZeneca AB v. Aurobindo Pharma Ltd., 16-4414 (D.N.J.) | July 20, 2016 | Hon. Mary L. Cooper | Nexium® 24HR (esomeprazole magnesium delayed-release capsules) |
6,369,085
7,411,070
|
Koios Pharms. LLC v. Medac Gesellschaft für klinische Spezialpräparate mbH, IPR2016-01370 (PTAB) | July 20, 2016 | N/A | Rasuvo® (methotrexate solution) | 8,664,231 |
Horizon Therapeutics, Inc. v. Lupin Ltd., 16-4438 (D.N.J.) | July 21, 2016 | Hon. Robert B. Kugler | Ravicti® (glycerol phenylbutyrate oral solution) |
9,254,278
9,326,966
|
Allergan, Inc. v. TWi Pharms., Inc., 16-0820 (E.D. Tex.) | July 21, 2016 | Hon. William C. Bryson | Restasis® (cyclosporine ophthalmic emulsion) |
8,629,111
8,633,162
8,642,556
8,648,048
8,685,930
9,248,191
|
Par Pharm., Inc. v. Novartis AG, IPR2016-01479 (PTAB) | July 22, 2016 | N/A | Afinitor® (everolimus tablets) | 9,006,224 |
Bayer Intellectual Property GmbH v. Breckenridge Pharm., Inc., 16-0628 (D. Del.) | July 25, 2016 | Hon. Sue L. Robinson | Xarelto® (rivaroxaban tablets) |
7,157,456
7,592,339
|
Fustibal LLC v. Bayer HealthCare, LLC, IPR2016-01490 (PTAB) | July 25, 2016 | N/A | Stivarga® (regorafenib tablets) | 8,637,553 |
Vivus, Inc. v. Hetero USA, Inc., 16-4560 (D.N.J.) | July 27, 2016 | Hon. Katharine S. Hayden | Stendra® (avanafil tablets) |
6,656,935
7,501,409
|
Sumitomo Dainippon Pharma Co., Ltd. v. Amneal Pharms. LLC, 16-4596 (D.N.J.) | July 29, 2016 | Hon. Stanley R. Chesler | Latuda® (lurasidone hydrochloride tablets) | 5,532,372 |
Novartis Pharms. Corp. v. Teva Pharms. USA, Inc., 16-0648 (D. Del.) | July 29, 2016 | Hon. Richard G. Andrews | Jadenu® (deferasirox tablets) | 6,465,504 |
AstraZeneca Pharms. LP v. Mylan Institutional LLC, 16-4612 (D.N.J.) | July 29, 2016 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant for injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
Galderma Labs., L.P. v. Taro Pharms. U.S.A., Inc., 16-2207 (N.D. Tex.) | July 29, 2016 | Hon. Ed Kinkeade | Epiduo® Forte (adapalene / benzoyl peroxide gel) |
8,445,543
8,785,420
8,809,305
|
AstraZeneca Pharms. LP v. Mylan Institutional LLC, 16-0669 (D. Del.) | Aug. 5, 2016 | Hon. Richard G. Andrews | Faslodex® (fulvestrant for injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
Shionogi Inc. v. Hi-Tech Pharmacal Co., Inc., 16-0676 (D. Del.) | Aug. 8, 2016 | Hon. Leonard P. Stark | Ulesfia® (benzyl alcohol lotion) |
6,793,931
7,294,342
|
Mylan Pharms. Inc. v. Boehringer Ingelheim International GMBH, IPR2016-01563 (PTAB) | Aug. 10, 2016 | N/A |
Tradjenta® (linagliptin tablets)
Jentadueto® (linagliptin / metformin hydrochloride tablets)
|
8,673,927 |
Mylan Pharms. Inc. v. Boehringer Ingelheim International GMBH, IPR2016-01564 (PTAB) | Aug. 10, 2016 | N/A |
Tradjenta® (linagliptin tablets)
Jentadueto® (linagliptin / metformin hydrochloride tablets)
|
8,846,695 |
Mylan Pharms. Inc. v. Boehringer Ingelheim International GMBH, IPR2016-01565 (PTAB) | Aug. 10, 2016 | N/A |
Tradjenta® (linagliptin tablets)
Jentadueto® (linagliptin / metformin hydrochloride tablets)
|
8,853,156 |
Mylan Pharms. Inc. v. Boehringer Ingelheim International GMBH, IPR2016-01566 (PTAB) | Aug. 10, 2016 | N/A |
Tradjenta® (linagliptin tablets)
Jentadueto® (linagliptin / metformin hydrochloride tablets)
|
9,173,859 |
Amneal Pharms. LLC v. Hospira, Inc., IPR2016-01577 (PTAB) | Aug. 10, 2016 | N/A | Precedex® (dexmedetomidine hydrochloride for injection) | 8,242,158 |
Amneal Pharms. LLC v. Hospira, Inc., IPR2016-01578 (PTAB) | Aug. 10, 2016 | N/A | Precedex® (dexmedetomidine hydrochloride for injection) | 8,338,470 |
Amneal Pharms. LLC v. Hospira, Inc., IPR2016-01579 (PTAB) | Aug. 10, 2016 | N/A | Precedex® (dexmedetomidine hydrochloride for injection) | 8,455,527 |
Amneal Pharms. LLC v. Hospira, Inc., IPR2016-01580 (PTAB) | Aug. 10, 2016 | N/A | Precedex® (dexmedetomidine hydrochloride for injection) | 8,648,106 |
Wockhardt Bio AG v. Janssen Oncology, Inc., IPR2016-01582 (PTAB) | Aug. 10, 2016 | N/A | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
Lupin Atlantis Holdings, S.A. v. InvaGen Pharms., Inc., 16-0708 (D. Del.) | Aug. 11, 2016 | Hon. Sue L. Robinson | Antara® (fenofibrate capsules) |
8,026,281
9,314,447
|
Horizon Pharma, Inc. v. Actavis Labs. FL., Inc., 16-4916 (D.N.J.) | Aug. 11, 2016 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
8,945,621
9,220,698
9,345,695
|
Horizon Pharma, Inc. v. Dr. Reddy’s Labs. Inc., 16-4918 (D.N.J.) | Aug. 11, 2016 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
8,945,621
9,220,698
9,345,695
|
Horizon Pharma, Inc. v. Lupin Ltd., 16-4920 (D.N.J.) | Aug. 11, 2016 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
8,945,621
9,220,698
9,345,695
|
Horizon Pharma, Inc. v. Mylan Pharms. Inc., 16-4921 (D.N.J.) | Aug. 11, 2016 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
8,945,621
9,220,698
9,345,695
|
Gilead Sciences, Inc. v. Hetero Drugs Ltd., 16-4938 (D.N.J.) | Aug. 11, 2016 | Hon. Renee Marie Bumb | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245
6,703,396
8,592,397
8,716,264
|
Jazz Pharms., Inc. v. Roxane Labs., Inc., 16-4971 (D.N.J.) | Aug. 12, 2016 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 8,731,963 |
Lupin Atlantis Holdings, S.A. v. InvaGen Pharms., Inc., 16-4535 (E.D.N.Y.) | Aug. 12, 2016 | Hon. Brian M. Cogan | Antara® (fenofibrate capsules) |
8,026,281
9,314,447
|
Horizon Pharma Ireland Ltd. v. Actavis Labs. UT, Inc., 16-5051 (D.N.J.) | Aug. 18, 2016 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
9,339,551
9,339,552
9,375,412
9,370,501
|
Horizon Pharma Ireland Ltd. v. Lupin Ltd., 16-5054 (D.N.J.) | Aug. 18. 2016 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
9,339,551
9,339,552
9,375,412
9,370,501
|
Aurobindo Pharma Ltd. v. AstraZeneca AB, 16-5079 (D.N.J.) | Aug. 18, 2016 | Hon. Mary L. Cooper | Prilosec OTC® (omeprazole magnesium delayed release tablets) |
6,403,616
6,428,810
|
Torrent Pharms. Ltd. v. UCB Pharma GMBH, IPR2016-01636 (PTAB) | Aug. 18, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 6,858,650 |
Apotex Inc. v. Alcon Research, Ltd., IPR2016-01640 (PTAB) | Aug. 18, 2016 | N/A | Pazeo® (olopatadine hydrochloride ophthalmic solution) | 8,791,154 |
Galderma Labs., L.P. v. Perrigo UK Finco L.P., 16-0732 (D. Del.) | Aug. 19, 2016 | Hon. Leonard P. Stark | Mirvaso® Gel (brimonidine topical gel) |
7,439,241
8,426,410
8,859,551
8,410,102
8,513,247
8,513,249
|
Reckitt Benckiser LLC v. Sun Pharm. Indus., Ltd., 16-5133 (D.N.J.) | Aug. 22, 2016 | Hon. Renee Marie Bumb | Mucinex® (guaifenesin extended-release tablets) |
6,372,252
6,955,821
7,838,032
|
Alembic Pharms. Ltd. v. UCB Pharma GMBH, IPR2016-01596 (PTAB) | Aug. 22, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 6,858,650 |
Amerigen Pharms. Ltd. v. UCB Pharma GMBH, IPR2016-01665 (PTAB) | Aug. 22, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 6,858,650 |
Shire Development LLC v. Alkem Labs. Ltd., 16-0747 (D. Del.) | Aug. 24, 2016 | Hon. Leonard P. Stark | Fosrenol® (lanthanum carbonate oral powder) |
5,968,976
7,465,465
8,980,327
9,023,397
|
Otsuka Pharm. Co., Ltd. v. Ajanta Pharma Ltd., 16-5288 (D.N.J.) | Aug. 29, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,359,302 |
Galdrema Labs., L.P. v. Seegpharm S.A., 16-2497 (N.D. Tex.) | Aug. 29, 2016 | Hon. David C. Godbey | MetroGel® (metronidazole topical gel) |
6,881,726
7,348,317
|
Neos Therapeutics, Inc. v. Actavis Labs. FL, Inc., 16-0766 (D. Del.) | Sept. 1, 2016 | Hon. Gregory M. Sleet | Adzenys XR-ODT™ (amphetamine extended-release orally disintegrating tablets) |
8,709,491
8,840,924
9,017,731
9,265,737
|
Otsuka Pharm. Co., Ltd. v. Macleods Pharms. Ltd., 16-5400 (D.N.J.) | Sept. 2, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,359,302 |
Eli Lilly and Co. v. Sun Pharma Indus. Ltd., 16-0518 (E.D. Va.) | Sept. 2, 2016 | Hon. Raymond A. Jackson | Cialis® (tadalafil tablets) | 6,943,166 |
Eli Lilly and Co. v. Teva Pharms. (USA) Inc., 16-0519 (E.D. Va.) | Sept. 2, 2016 | Hon. Raymond A. Jackson | Cialis® (tadalafil tablets) | 6,943,166 |
Eli Lilly and Co. v. Zydus Pharms. (USA), Ltd., 16-0520 (E.D. Va.) | Sept. 2, 2016 | Hon. Raymond A. Jackson | Cialis® (tadalafil tablets) | 6,943,166 |
Eli Lilly and Co. v. Actavis Labs. UT, Inc., 16-1119 (E.D. Va.) | Sept. 2, 2016 | Hon. Anthony J. Trenga | Cialis® (tadalafil tablets) | 6,943,166 |
Eli Lilly and Co. v. Alembic Pharms. Ltd., 16-1120 (E.D. Va.) | Sept. 2, 2016 | Hon. Anthony J. Trenga | Cialis® (tadalafil tablets) | 6,943,166 |
Eli Lilly and Co. v. Aurobindo Pharma Ltd., 16-1121 (E.D. Va.) | Sept. 2, 2016 | Hon. Anthony J. Trenga | Cialis® (tadalafil tablets) | 6,943,166 |
Eli Lilly and Co. v. Mylan Pharms. Inc., 16-1122 (E.D. Va.) | Sept. 2, 2016 | Hon. Anthony J. Trenga | Cialis® (tadalafil tablets) | 6,943,166 |
West-Ward Pharms. Corp. v. Par Pharm. Inc., 16-5456 (D.N.J.) | Sept. 8, 2016 | Hon. Brian R. Martinotti | Mitigare® (colchicine capsules) | 8,927,607 |
Meda Pharms. Inc. v. Perrigo UK Finco Ltd. Partnership, 16-0794 (D. Del.) | Sept. 9, 2016 | Hon. Leonard P. Stark | Dymista® (azelastine hydrochloride / fluticasone propionate nasal spray) |
8,168,620
9,259,428
|
Unimed Pharms., LLC v. TWi Pharms., Inc., 16-0810 (D. Del.) | Sept. 16, 2016 | Hon. Richard G. Andrews | AndroGel® (testosterone gel) |
6,503,894
8,729,057
8,741,881
8,754,070
8,759,329
9,125,816
9,132,089
|
Sanofi-Aventis U.S. LLC v. Merck Sharp & Dohme Corp., 16-0812 (D. Del.) | Sept. 16, 2016 | Hon. Richard G. Andrews | Lantus® / Lantus® SoloSTAR® (insulan glargine for injection) |
7,918,833
8,512,297
8,556,864
8,603,044
8,992,486
8,679,069
9,011,391
9,233,211
7,476,652
7,713,930
|
Sanofi-Aventis U.S. LLC v. Sandoz Inc., 16-5678 (D.N.J.) | Sept. 16, 2016 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel for injection) |
5,847,170
8,927,592
|
Otsuka Pharm. Co., Ltd. v. Orchid Pharma Ltd., 16-5688 (D.N.J.) | Sept. 16, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,359,302 |
Otsuka Pharm. Co., Ltd. v. Intas Pharms. Ltd., 16-5743 (D.N.J.) | Sept. 19, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
9,359,302
9,387,182
|
Genzyme Corp. v. Mylan Labs. Ltd., 16-5828 (D.N.J.) | Sept. 19, 2016 | Hon. Stanley R. Chesler | Clolar® (clofarabine for injection) | 5,661,136 |
Amgen Inc. v. Aurobindo Pharma Ltd., 16-0853 (D. Del.) | Sept. 22, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
Amgen Inc. v. Micro Labs Ltd., 16-0854 (D. Del.) | Sept. 22, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
Amgen Inc. v. Watson Labs., Inc., 16-0855 (D. Del.) | Sept. 22, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
Eli Lilly and Co. v. Cipla Ltd., 16-1208 (E.D. Va.) | Sept. 22, 2016 | Hon. Anthony J. Trenga | Cialis® (tadalafil tablets) | 6,943,166 |
Impax Labs., Inc. v. Par Pharm., Inc., 16-0856 (D. Del.) | Sept. 23, 2016 | Hon. Richard G. Andrews | Zomig® (zolmitriptan nasal spray) | 7,220,767 |
Otsuka Pharm. Co., Ltd. v. Macleods Pharms. Ltd., 16-5949 (D.N.J.) | Sept. 23, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,387,182 |
Genzyme Corp. v. Mylan Labs. Ltd., 16-0188 (N.D.W.V.) | Sept. 23, 2016 | Hon. Irene M. Keeley | Clolar® (clofarabine for injection) | 5,661,136 |
Otsuka Pharm. Co., Ltd. v. Alkem Labs. Ltd., 16-6067 (D.N.J.) | Sept. 26, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,359,302 |
Silvergate Pharms., Inc. v. Bionpharma, Inc., 16-0876 (D. Del.) | Sept. 28, 2016 | Hon. Sue L. Robinson | Epaned® (enalapril maleate for oral solution) | 8,568,747 |
Hospira, Inc. v. Par Sterile Products, LLC, 16-0879 (D. Del.) | Sept. 29, 2016 | Hon. Richard G. Andrews | Precedex® (dexmedetomidine hydrochloride for injection) |
8,242,158
8,338,470
8,455,527
8,648,106
|
Amgen Inc. v. Cipla Ltd., 16-0880 (D. Del.) | Sept. 29, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
Amgen Inc. v. Strides Pharma Global PTE Ltd., 16-0881 (D. Del.) | Sept. 29, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
Amgen Inc. v. Sun Pharm. Indus., Ltd., 16-0882 (D. Del.) | Sept. 29, 2016 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet hydrochloride tablets) | 9,375,405 |
Adare Pharms., Inc. v. Apotex, Inc., 16-0884 (D. Del.) | Sept. 29, 2016 | Hon. Sue L. Robinson | Amrix® (cyclobenzaprine hydrochloride extended-release capsules) | 9,399,025 |
Pfizer Inc. v. Aurobindo Pharma Ltd., 16-0886 (D. Del.) | Sept. 30, 2016 | Hon. Gregory M. Sleet | Toviaz® (fesoterodine fumarate extended-release tablets) |
6,858,650
7,384,980
7,855,230
7,985,772
8,338,478
|
Arena Pharms., Inc. v. Lupin Ltd., 16-0887 (D. Del.) | Sept. 30, 2016 | Hon. Richard G. Andrews | Belviq® (lorcaserin hydrochloride tablets) |
6,953,787
7,514,422
7,977,329
8,207,158
8,273,734
8,546,379
8,575,149
8,999,970
9,169,213
|
GENERICally Speaking Fall 2016
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.